open access

Vol 14, No 1 (2011)
Original articles
Published online: 2011-07-12
Submitted: 2012-01-23
Get Citation

The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves’ disease and toxic nodular goitre

Franciszek Rogowski, Saeid Abdelrazek, Piotr Szumowski, Anna Zonenberg, Adam Parfienczyk, Agnieszka Sawicka
Nucl. Med. Rev 2011;14(1):9-15.

open access

Vol 14, No 1 (2011)
Original articles
Published online: 2011-07-12
Submitted: 2012-01-23

Abstract

BACKGROUND: The aim of the study was to achieve an effective target dose in the thyroid by increasing the effective half-life (Teff) of 131I by use of iodide (127I) two days after 131I therapy in patients with hyperthyroidism with low Teff.
MATERIAL AND METHODS: The study was carried out in two groups. Group A — 41 patients, and Group B — 14 patients, all the patients were with hyperthyroidism with Teff less than 3 days qualified for 131I therapy. Only group A patients received 600 μg of iodide a day for 3 days, two days after 131I therapy. Radioiodine uptake (RAIU) after 24 and 48 hours, thyroid scintiscan and ultrasonography were done before and after 12 months of 131I therapy.
RESULTS: In group A a significant increase was seen in the Teff (5 days on average) resulting in an increase in the energy target dose by 28% and 37%, in patients with Graves’ disease (GD) and toxic nodular goitre (TNG), respectively. After one year of therapy 50% of GD and 93% of TNG patients achieved euthyroidism; 28% of GD and 3% of TNG patients were in hypothyroidism. In Group B, all the patients had radioiodine treatment failure and received a second therapeutic dose of 131I.
CONCLUSIONS: Administration of 127I after 131I treatment can lead to an increase in its effective half-life. This will also increase the absorbed energy dose in thyroid tissue, thereby improving therapeutic outcome without administration of a higher or second dose of 131I. This may minimize whole-body exposure to radiation and reduces the cost of treatment.
Nuclear Med Rev 2011; 14, 1: 9–15

Abstract

BACKGROUND: The aim of the study was to achieve an effective target dose in the thyroid by increasing the effective half-life (Teff) of 131I by use of iodide (127I) two days after 131I therapy in patients with hyperthyroidism with low Teff.
MATERIAL AND METHODS: The study was carried out in two groups. Group A — 41 patients, and Group B — 14 patients, all the patients were with hyperthyroidism with Teff less than 3 days qualified for 131I therapy. Only group A patients received 600 μg of iodide a day for 3 days, two days after 131I therapy. Radioiodine uptake (RAIU) after 24 and 48 hours, thyroid scintiscan and ultrasonography were done before and after 12 months of 131I therapy.
RESULTS: In group A a significant increase was seen in the Teff (5 days on average) resulting in an increase in the energy target dose by 28% and 37%, in patients with Graves’ disease (GD) and toxic nodular goitre (TNG), respectively. After one year of therapy 50% of GD and 93% of TNG patients achieved euthyroidism; 28% of GD and 3% of TNG patients were in hypothyroidism. In Group B, all the patients had radioiodine treatment failure and received a second therapeutic dose of 131I.
CONCLUSIONS: Administration of 127I after 131I treatment can lead to an increase in its effective half-life. This will also increase the absorbed energy dose in thyroid tissue, thereby improving therapeutic outcome without administration of a higher or second dose of 131I. This may minimize whole-body exposure to radiation and reduces the cost of treatment.
Nuclear Med Rev 2011; 14, 1: 9–15
Get Citation

Keywords

non-radioactive iodine-127; toxic nodular goitre; Graves’ disease; radioiodine therapy

About this article
Title

The influence of non-radioactive iodine (127I) on the outcome of radioiodine (131I) therapy in patients with Graves’ disease and toxic nodular goitre

Journal

Nuclear Medicine Review

Issue

Vol 14, No 1 (2011)

Pages

9-15

Published online

2011-07-12

Bibliographic record

Nucl. Med. Rev 2011;14(1):9-15.

Keywords

non-radioactive iodine-127
toxic nodular goitre
Graves’ disease
radioiodine therapy

Authors

Franciszek Rogowski
Saeid Abdelrazek
Piotr Szumowski
Anna Zonenberg
Adam Parfienczyk
Agnieszka Sawicka

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl